Biotech firm's balance sheet smells suspicious.
Advanced Cell Technology (OTC: BB: ACTC, Stock Forum) recently had a private placement which brought in just over $3 million. It's a good thing. Otherwise the company might not be around.
ACTC's business is working on human embryonic stem cells. Whether it is doing a good job with that work is open to question. An "expert" who follows the company recently said the "ACTCellerate technology will greatly hasten the translation of human embryonic stem cell-based therapies into safe and effective products." So, why does the company trade at just over eight cents down from a 52-week high of 78 cents? The answer to that is not in any of the ACTC PR.
ACTC accounting practices leave something to be desired. The Audit Committee at the firm recently said that certain of the company's financial reports were off because of improper accounting for debentures and warrants.
Last month, ACTC announced it could not file its 10Q on time. A look at the 10K shows that the number of warrants and options outstanding represent huge dilution potential. In 2007 ACTC lost over $23 million.
A good stock to bury before it starts to stink.
Stockhouse Conflict and Disclosure Policy:
Stockhouse publishing Ltd., owners and operators of Stockhouse.com, has established the following rules to ensure that there is no appearance of impropriety on the part of any Stockhouse Editorial writers ("Writers"). The content of Stockhouse Editorial articles (the "Articles") are the opinion of the Writer and any reliance on the content of these articles is at your sole risk. Our Writers are not registered investment advisors. You should not make any kind of investment decision in relation to Articles or stocks discussed in them without obtaining advice from a registered investment advisor.
Facts relied upon by our Writers are generally provided by the subject companies or gathered by our Writers from other public and/or private sources. These facts may be in error and if so, the opinions of our Writers may be materially different.
Writers may own, buy, or sell shares in public companies mentioned in their Articles, but in the Article they must prominently state their ownership position. Thus, a conflict may exist. Writers are not permitted to write Articles that attempt to benefit persons connected to the Writer, such as family or friends, except where disclosure is made in the same way as if the Writer him/herself owns stock.
Writers cannot solicit, accept, or agree to receive anything of value given or paid with the intent of influencing their Articles.
Stockhouse notifies each Writer about these rules, and we rely on the integrity of our Writers to ensure that our rules are followed.
